3 results on '"Michel Pugeat"'
Search Results
2. Effects of human chorionic gonadotropin, androgens, adrenocorticotropin hormone, dexamethasone and hyperprolactinemia on plasma sex steroid-binding protein
- Author
-
Michel Pugeat, Maguelone G. Forest, Annick Lecoq, and Michel David
- Subjects
Adult ,Male ,medicine.medical_specialty ,Population ,Fluoxymesterone ,Adrenocorticotropic hormone ,Chorionic Gonadotropin ,General Biochemistry, Genetics and Molecular Biology ,Dexamethasone ,Human chorionic gonadotropin ,Sex hormone-binding globulin ,History and Philosophy of Science ,Adrenocorticotropic Hormone ,Internal medicine ,Sex Hormone-Binding Globulin ,Medicine ,Humans ,education ,Child ,hirsutism ,education.field_of_study ,biology ,business.industry ,General Neuroscience ,Infant ,medicine.disease ,Hyperprolactinemia ,Endocrinology ,Child, Preschool ,biology.protein ,Androgens ,Female ,business ,Hormone ,medicine.drug - Abstract
This presentation reports the effects of androgens, glucocorticoids and some pituitary hormones on plasma sex steroid-binding protein (SBP). The latter was measured by a solid phase method after desteroidation of the plasma. An hCG test (1500 I.U. every other day X 7) was given to 60 boys. In the children with a normal testosterone (T) rise, plasma SBP decreased (% of basal values) either significantly (38.3 +/- 9.3%, group A; n = 29), or moderately (13.4 +/- 4.4%, group B; n = 9) or did not change (-1.6 +/- 6.4%, group C; n = 10). In the 3 infants tested at an age when SBP normally rise sharply, hCG partially prevented this rise. The administration of either fluoxymesterone (10 mg/m2 for 10 days) or depot-T (4 I.M. injections of 100 mg/m2 every 2 weeks) induced a significant drop (about 2-fold) in plasma SBP in a control group of infants or children, but did not change SBP in 3 infants with the androgen insensitivity syndrome. A single injection of 0.25 mg of ACTH did not significantly alter SBP levels. In contrast, at the end of a 3-day ACTH test (0.5 mg/m2 12 hourly X 6) SBP levels had significantly decreased (mean 35% fall) with no age or sex differences, and with no correlation with the cortisol levels reached. However, the lowering effect of ACTH on SBP levels is likely mediated by glucocorticoids, since its effect was reproduced by high doses (8 mg/day for 3 days) of dexamethasone given at once or after 3 days of treatment at lower dose (20 micrograms/kg BW). It would appear that the depressive effect of ACTH and/or dexamethasone is observed for a threshold dose of glucocorticoids (greater than 5-fold physiological levels) and a certain time (greater than or equal to 3 days) of exposure. The mechanism by which androgens and glucocorticoids lower SBP levels in vivo is not yet understood. From recent experiments, showing that both stimulate the secretion of SBP in hepatoma cells in vitro, it would appear that both hormones may alter SBP metabolism. In a selected population of hyperprolactinemic women, with normal weight and no hirsutism, plasma SBP levels were found in the normal female range. The discrepancy with previous studies in the literature may be explained by differences in the degree of hyperprolactinemia and/or associated hyperandrogenim. This study further documents the multifactorial and intricated hormonal influences involved in the regulation of plasma SBP in vivo.
- Published
- 1988
3. Sex steroid-binding protein in nonendocrine diseases
- Author
-
Maguelone G. Forest, Michel Pugeat, J. Tourniaire, Hervé Lejeune, Mindy S. Kurzer, B. Estour, and D. Garrel
- Subjects
medicine.medical_specialty ,Cirrhosis ,business.industry ,medicine.drug_class ,General Neuroscience ,Sex Steroid-Binding Protein ,Osteoporosis ,Lipid metabolism ,medicine.disease ,Androgen ,General Biochemistry, Genetics and Molecular Biology ,Endocrinology ,History and Philosophy of Science ,Estrogen ,Internal medicine ,Sex Hormone-Binding Globulin ,Medicine ,Endocrine system ,Humans ,Disease ,cardiovascular diseases ,business ,circulatory and respiratory physiology ,Hormone - Abstract
In humans, sex steroid-binding protein (SBP) is a protein from the liver which binds with high affinity sex steroid hormones. The plasma concentration of SBP is regulated in part by hormonal factors. It has been shown that estrogens and/or thyroid hormones increase the production of SBP by hepatoma cell lines. It is therefore assumed that the increase in SBP levels in patients given oral estrogens or thyroid hormones is the consequence of a direct stimulation of the liver production of SBP by these hormones. The effects of androgen, progestagen and glucocorticoid hormones are unclear or still a matter of controversy. Moreover, the regulation of the metabolic clearance rate of SBP and the influence of nonhormonal factors on the production of SBP are still speculative. Changes in SBP have been described in a few nonendocrine diseases. A slight hormonal dysfunction may be either the primary or the sole cause of the changes in SBP occurring in these diseases. As an example, elevated SBP levels have been reported in men with liver cirrhosis together with testicular hypofunction and increased estrogen levels. It is therefore difficult to demonstrate that the increase in SBP is due to the liver dysfunction rather than to the endocrinological side effects of cirrhosis. The aim of this review is to present some aspects of the nonhormonal regulation of SBP. There is accumulating evidence in the literature for a relation between SBP levels and body weight and fat distribution, energy balance, diet and physical activity, and lipid metabolism. Therefore, it is tempting to propose that SBP is an index which reflects the status of endocrine, metabolic and nutritional functions. Measurement of SBP may be considered of interest in the light of previous epidemiological studies and the preventive approach to diseases such as hormone dependent tumors, cardiovascular diseases and osteoporosis.
- Published
- 1988
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.